Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL – Research Report). The ...

Samidoun, a Pro-Palestinian and anti-Israel advocacy group that helps organize protests, is sharing its plans ahead of the October 7 anniversary of the start of the Israel-Hamas war.

Jefferies analyst Akash Tewari maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $169.00.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...